Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7
Victor B. Pastor,
Sushree S. Sahoo,
Jessica Boklan,
Georg C. Schwabe,
Ebru Saribeyoglu,
Brigitte Strahm,
Dirk Lebrecht,
Matthias Voss,
Yenan T. Bryceson,
Miriam Erlacher,
Gerhard Ehninger,
Marena Niewisch,
Brigitte Schlegelberger,
Irith Baumann,
John C. Achermann,
Akiko Shimamura,
Jochen Hochrein,
Ulf Tedgård,
Lars Nilsson,
Henrik Hasle,
Melanie Boerries,
Hauke Busch,
Charlotte M. Niemeyer,
Marcin W. Wlodarski
Affiliations
Victor B. Pastor
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany;Faculty of Biology, University of Freiburg, Germany
Sushree S. Sahoo
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany;Faculty of Biology, University of Freiburg, Germany;Spemann Graduate School of Biology and Medicine, University of Freiburg, Germany
Jessica Boklan
Center for Cancer and Blood Disorders, Phoenix Children’s Hospital, AZ, USA
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany
Dirk Lebrecht
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany
Matthias Voss
Department of Medicine, Huddinge, Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden
Yenan T. Bryceson
Department of Medicine, Huddinge, Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden
Miriam Erlacher
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany;German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
Gerhard Ehninger
Internal Medicine of Hematology/Medical Oncology, University Hospital, Dresden, Germany
Marena Niewisch
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany
Brigitte Schlegelberger
Institute of Human Genetics, Hannover Medical School, Germany
Irith Baumann
Clinical Centre South West, Department of Pathology, Böblingen Clinics, Germany
John C. Achermann
Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, UK
Akiko Shimamura
Boston Children’s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, MA, USA
Jochen Hochrein
Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany
Ulf Tedgård
Department of Pediatric Oncology and Hematology, Skåne University Hospital, Lund, Sweden
Lars Nilsson
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
Henrik Hasle
Department of Pediatrics, Aarhus University Hospital, Denmark
Melanie Boerries
German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany;Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany
Hauke Busch
Institute of Molecular Medicine and Cell Research, University of Freiburg, Germany;Lübeck Institute of Experimental Dermatology, Germany
Charlotte M. Niemeyer
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany;German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
Marcin W. Wlodarski
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany;German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
Familial myelodysplastic syndromes arise from haploinsufficiency of genes involved in hematopoiesis and are primarily associated with early-onset disease. Here we describe a familial syndrome in seven patients from four unrelated pedigrees presenting with myelodysplastic syndrome and loss of chromosome 7/7q. Their median age at diagnosis was 2.1 years (range, 1–42). All patients presented with thrombocytopenia with or without additional cytopenias and a hypocellular marrow without an increase of blasts. Genomic studies identified constitutional mutations (p.H880Q, p.R986H, p.R986C and p.V1512M) in the SAMD9L gene on 7q21, with decreased allele frequency in hematopoiesis. The non-random loss of mutated SAMD9L alleles was attained via monosomy 7, deletion 7q, UPD7q, or acquired truncating SAMD9L variants p.R1188X and p.S1317RfsX21. Incomplete penetrance was noted in 30% (3/10) of mutation carriers. Long-term observation revealed divergent outcomes with either progression to leukemia and/or accumulation of driver mutations (n=2), persistent monosomy 7 (n=4), and transient monosomy 7 followed by spontaneous recovery with SAMD9L-wildtype UPD7q (n=2). Dysmorphic features or neurological symptoms were absent in our patients, pointing to the notion that myelodysplasia with monosomy 7 can be a sole manifestation of SAMD9L disease. Collectively, our results define a new subtype of familial myelodysplastic syndrome and provide an explanation for the phenomenon of transient monosomy 7. Registered at: www.clinicaltrials.gov; #NCT00047268.